Back to Browse Journals » International Journal of Nephrology and Renovascular Disease » Volume 1

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs

Authors James B Wetmore, L Darryl Quarles

Published 13 November 2008 Volume 2008:1 Pages 5—17

DOI http://dx.doi.org/10.2147/IJNRD.S4368

Review by Single-blind

Peer reviewer comments 7

James B Wetmore1, L Darryl Quarles1,2

1Department of Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS, USA; 2The Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA

Abstract: There is a growing understanding of the pathophysiology of secondary hyperparathyroidism (SHPT) and a recent emergence of new agents for SHPT treatment in patients with advanced kidney disease. At the same time, appreciation that mineral metabolic derangements promote vascular calcification and contribute to excess mortality, along with recognition of potentially important “non-classical” actions of vitamin D, have prompted the nephrology community to reexamine the use of various SHPT treatments, such as activated vitamin D sterols, phosphate binders, and calcimimetics. In this review, the evidence for treatment of SHPT with calcimimetics and vitamin D analogs is evaluated, with particular consideration given to recent clinical trials that have reported encouraging findings with cinacalcet use. Additionally, several controversies in the pathogenesis and treatment of SHPT are explored. The proposition that calcitriol deficiency is a true pathological state is challenged, the relative importance of the vitamin D receptor and the calcium sensing receptor in parathyroid gland function is summarized, and the potential relevance of non-classical actions of vitamin D for patients with advanced renal disease is examined. Taken collectively, the balance of evidence now supports a treatment paradigm in which calcimimetics are the most appropriate primary treatment for SHPT in the majority of end stage renal disease patients, but which nevertheless acknowledges an important role for modest doses of activated vitamin D sterols.

Keywords: secondary hyperparathyroidism, vitamin D, vitamin D receptor, calcium sensing receptor, calcimimetics, kidney disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review

Patterson MF, Borish L, Kennedy JL

Journal of Asthma and Allergy 2015, 8:125-134

Published Date: 3 November 2015

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

Marslin G, Revina AM, Khandelwal VKM, Balakumar K, Prakash J, Franklin G, Sheeba CJ

International Journal of Nanomedicine 2015, 10:3163-3170

Published Date: 24 April 2015

Making the certainty based marking pilot study a reality

Stone BA, Lemon TI

Advances in Medical Education and Practice 2013, 4:101-102

Published Date: 7 May 2013

Disparity in risk factor pattern in premature versus late-onset coronary artery disease: a survey of 15,381 patients

Reibis R, Treszl A, Wegscheider K, Bestehorn K, Karmann B, Voeller H

Vascular Health and Risk Management 2012, 8:473-481

Published Date: 17 August 2012

Nephrolithiasis-induced end stage renal disease

M Ounissi, T Gargueh, M Mahfoudhi, et al

International Journal of Nephrology and Renovascular Disease 2010, 3:21-26

Published Date: 11 March 2010

Management of superficial basal cell carcinoma: focus on imiquimod

Beverly Raasch

Clinical, Cosmetic and Investigational Dermatology 2009, 2:65-75

Published Date: 11 June 2009

The use of everolimus in renal-transplant patients

Julio Pascual

International Journal of Nephrology and Renovascular Disease 2009, 2:9-21

Published Date: 2 June 2009

Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis

Claire M Payne, Carol Bernstein, Katerina Dvorak, Harris Bernstein

Clinical and Experimental Gastroenterology 2008, 1:19-47

Published Date: 16 December 2008